Japan’s Central Social Insurance Medical Council, which advises the health minister, approved Wednesday public health insurance coverage for donanemab, an Alzheimer’s medicine developed by U.S. drugmaker Eli Lilly & Co. The government set the drug’s price at 66,948 yen per 350-milligram vial. As a dip is required every month, it will cost a patient about 3.08 million yen per year. Treatment with donanemab will last up to 18 months. Due to the high costs, the government will provide subsidies to cap patients’ out-of-pocket expenses. As a result, most of the costs will be shouldered by the government. The insurance coverage will start Nov. 20.